I wonder if Pfizer's patent application could result in an application for a PRV since Friedrich's ataxia is a rare paediatric disease. It makes me further wonder if Pfizer and Resverlogix may be talking about some type of funding arrangement as to proceed down this road as they would both need to be involved if Apabetalone is Prizer's preferred BET inhibitor.  Since PRV's are worth hundreds of millions of dollars one would think it would be worth pursuing.  What would Pfizer pay to/invest in Resverlogix now to secure a shot at a PRV that would be worth north of $300 million? To me Pfizer now has at least 3 legitimate reasons to be very interested in RVX/Zenith, Apabetalone + Rosuvastatin could seriously dent Lipitor sales, Zen 3694 could potentially boost enzalutamide's efficacy and patent life and now perhaps the potential of a PRV?